Successful prevention of recurrent nasal polyposis by means of systemic low-dose IFN-α2a [1]

Journal of Allergy and Clinical Immunology

Volumn 108, Issue 1, 2001, Pages 141-

  Huber, M A ^a   Gall, H ^a   Gethoffer K ^a   Muhlmeier G ^a   Maier, H ^a   Peter, R U ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; INTERLEUKIN 5;

ADULT; CASE REPORT; DOSE RESPONSE; FEMALE; FLU LIKE SYNDROME; HUMAN; INFLAMMATION; LETTER; MALE; NOSE POLYP; PARANASAL SINUS; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE;

FEMALE; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; NASAL POLYPS; RECURRENCE;

EID: 0034913037     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.116288     Document Type: Letter

References (5)

1. Nasal polyposis: Eosinophils and interleukin-5
2. Recombinant interferon alpha selectively inhibits the production of IL-5 by human CD4+ cells
3. Therapeutic strategies for allergic diseases
4. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome
5. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome